Effect of Nepeta bracteata Benth. on allergic rhinitis symptoms: A randomized double-blind clinical trial

Hajiheydari, Mohammad Reza; Yarmohammadi, Mohammad Ebrahim; Izadi, Poopak; Jafari, Fatemeh; Emadi, Fatemeh; Emaratkar, Elham; Abtahi, Sayed Hamid Reza; Zargaran, Arman; Naseri, Mohsen

doi:10.4103/jrms.jrms_316_17

Cited by 14 publications

(12 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[1] Allergic Rhinitis (AR) as the most common allergic diseases has an ascending prevalence worldwide[23] that annually billion dollars paid for the treatment of physical and mental problems and disabilities of such patients that imposes a heavy burden on health services. [45] General principles of treatment are education and awareness, the avoidance of allergen, appropriate medicine use, and finally the immunotherapy application. [678] Given that complete allergen avoidance is not possible and administrations of current medicines are restricted because of their side effects and also decreased effectiveness following continuous consumption.…”

Section: Introductionmentioning

confidence: 99%

A significant decrease in the gene expression of interleukin-17 following the administration of synbiotic in patients with allergic rhinitis who underwent immunotherapy: A placebo-controlled clinical trial

et al. 2019

View full text Add to dashboard Cite

Background: Allergic Rhinitis (AR) is the most common allergic disease worldwide. The present study, evaluated effects of synbiotic on gene expression of interferon-gamma (IFN-γ), interleukin-4 (IL-4), interleukin-10 (IL-10), interleukin-17 (IL-17), transforming growth factor beta (TGF-β), and forkhead box P3 (FoxP3) in AR patients who received concomitant immunotherapy in a placebo-controlled clinical trial. Materials and Methods: Twenty AR patients were randomized in synbiotic and placebo groups and received cluster immunotherapy for 2 months. RNA was extracted from peripheral PBMCs, then the cDNA synthesized. Subsequently, SYBR Green real-time Reverse transcription polymerase chain reaction technique was employed for studying the expression of mentioned genes. In addition, SNOT-22 and mini-Rhinoconjunctivitis Quality of Life Questionnaire questionnaires were completed by patients. Data were analyzed before and also 2 and 6 months after intervention. Results: Clinical symptoms and quality of life were improved with immunotherapy, but there was no significant difference between the placebo and synbiotic groups. Gene expression of IFN-γ, TGF-β, and FoxP3 was increased whereas the gene expression of IL-4 and IL-10 decreased, but not significant. Interestingly, the gene expression of IL-17 in the synbiotic group was significantly decreased versus placebo after 2 months ( P = 0.001) and also at the end of intervention ( P = 0.0001) comparing with the time zero. Conclusion: Significant reduction in the IL-17 gene expression following administration of synbiotic versus placebo shows the importance of synbiotic in control of the immunopathogenesis of AR. Further studies with more samples are recommended. In addition, evaluating the effects of synbiotic in patients who do not undergo immunotherapy is suggested to get a better conclusion.

show abstract

Section: Introductionmentioning

confidence: 99%

A significant decrease in the gene expression of interleukin-17 following the administration of synbiotic in patients with allergic rhinitis who underwent immunotherapy: A placebo-controlled clinical trial

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Reporting bias was considered to be high in six studies (20.7%) [ 28 , 35 , 39 , 42 , 43 , 46 ] where these studies did not report baseline data of the participants and/or relevant clinical outcome(s) of allergic rhinitis. Other biases were considered to be unclear in 16 studies (55.2%) [ 25 , 27 , 28 , 31 , 34 – 43 , 46 , 48 ] due to unclear funding source or were industry-sponsored, conducted, or authored trials. The remaining three with unclear risk for other biases were cross-over studies.…”

Section: Resultsmentioning

confidence: 99%

“…Rhinorrhoea . Pooled estimates from six studies [ 27 , 28 , 30 , 31 , 42 , 48 ] showed that medicinal plants may have no effect on rhinorrhoea (SMD -0.85, 95% CI -1.73 to 0.04; participants = 399; studies = 6; I 2 = 94%). The evidence is very uncertain.…”

Section: Resultsmentioning

confidence: 99%

Medicinal plants for allergic rhinitis: A systematic review and meta-analysis

Lim,

Lau,

Zolkifli

et al. 2024

PLoS ONE

View full text Add to dashboard Cite

Herbal medicine is popularly used among patients who suffer from allergic rhinitis. This systematic review and meta-analysis was conducted to evaluate the efficacy and safety of single medicinal plants in the management of allergic rhinitis. We searched MEDLINE, CENTRAL, and Web of Science for randomised controlled trials which evaluated the use of single medicinal plant for allergic rhinitis among adults and children. Twenty-nine randomised controlled trials (n = 1879) were eligible while 27 (n = 1769) contributed data for meta-analyses. Most studies (studies = 20) compared medicinal plants against placebo and Petasites hybridus was most frequently investigated (studies = 5). Very-low-to-low-certainty evidence suggests that compared to placebo, single medicinal plants may improve overall total nasal symptoms (SMD -0.31, 95% CI -0.59 to -0.02; participants = 249; studies = 5; I2 = 21%) especially nasal congestion and sneezing; and rhinoconjunctivitis quality of life (RQLQ) scores (MD -0.46, 95% CI -0.84 to -0.07; participants = 148; studies = 3; I2 = 0%). Moderate-certainty evidence show no clear differences between single medicinal plants and antihistamine in overall symptoms (Total nasal symptoms: SMD -0.14, 95% CI -0.46 to 0.18; participants = 149; studies = 2; I2 = 0%). As adjunctive therapy, moderate-certainty evidence shows that medicinal plants improved SNOT-22 scores when given as intranasal treatment (MD -7.47, 95% CI -10.75 to -4.18; participants = 124; studies = 2; I2 = 21%). Risk of bias domains were low or not clearly reported in most studies while heterogeneity was substantial in most pooled outcomes. Route of administration and age were identified to be plausible source of heterogeneity for certain outcomes. Medicinal plants appear to be well tolerated up to 8 weeks of use. Clear beneficial evidence of medicinal plants for allergic rhinitis is still lacking. There is a need for improved reporting of herbal trials to allow for critical assessment of the effects of each individual medicinal plant preparation in well-designed future clinical studies.

show abstract

“…The concentration of the phenolics content in the hydroalcoholic extract of the R. damascena preparation was determined via the spectrophotometric method and the Folin-Ciocalteu's reagent, NaHCO 3 solution, and gallic acid as the standard (23,24). Then, the content of phenolics in the extracts was expressed in terms of gallic acid equivalent (mg of GA/g of extract).…”

Section: Total Phenolic and Flavonoid Content Assaymentioning

confidence: 99%

“…Then, the content of phenolics in the extracts was expressed in terms of gallic acid equivalent (mg of GA/g of extract). Further, the spectrophotometry method via AlCl3 solution and the catechin standard was conducted for the flavonoid content (24,25). The content of flavonoids in the extracts was expressed in terms of the catechin equivalent (mg of CAT/g of the extract).…”

Section: Total Phenolic and Flavonoid Content Assaymentioning

confidence: 99%

Evaluation of the Effect of Rosa damascena Mill. Product on Constipation During Pregnancy: A Single-Arm Clinical Trial

Emaratkar¹,

Nili²,

Hadavand³

et al. 2020

International Journal of Women’s Health and Reproduction Scienc

Self Cite

View full text Add to dashboard Cite

Objectives: Constipation is one of the most common issues at the time of pregnancy. Traditional Persian medicine (TPM) has always emphasized the use of safe laxatives to relieve constipation during pregnancy.The present study aimed to investigate the effect of Rosa damascena Mill. products on constipation and the quality of life during pregnancy. Materials and Methods: This is a single-arm clinical trial study on 35 pregnant women (14-34 weeks) with constipation diagnosed on the basis of Rome IV criteria in Tehran and Qom, Iran during 2018-2019. The consumption of R. damascena products was recommended daily for 4 weeks. Then, the severity of constipation and the quality of life were assessed via the Rome IV criteria and the World Health Organization (WHO) quality of life questionnaires (WHOQOL-BREF), respectively. Results: This study was performed on 35 pregnant women (14-34 weeks). The consumption of R. damascena products decreased the score of Rome IV criteria (Mean9.4 to 1.1) while increasing the frequency of bowel movements and improving the overall quality of life (P < 0.001). The predominant constipation signs, including straining, lumpy and hard stools, a sensation of incomplete evacuation, a sensation of anorectal obstruction, manual facilitation maneuvers, and less than 3 spontaneous bowel movements per week significantly improved after the consumption of R. damascena products (P < 0.001). Conclusions: Rosa damascena products can effectively treat constipation and enhance the quality of life.

show abstract

Effect of Nepeta bracteata Benth. on allergic rhinitis symptoms: A randomized double-blind clinical trial

Cited by 14 publications

References 18 publications

A significant decrease in the gene expression of interleukin-17 following the administration of synbiotic in patients with allergic rhinitis who underwent immunotherapy: A placebo-controlled clinical trial

A significant decrease in the gene expression of interleukin-17 following the administration of synbiotic in patients with allergic rhinitis who underwent immunotherapy: A placebo-controlled clinical trial

Medicinal plants for allergic rhinitis: A systematic review and meta-analysis

Evaluation of the Effect of Rosa damascena Mill. Product on Constipation During Pregnancy: A Single-Arm Clinical Trial

Contact Info

Product

Resources

About